Drug development

#Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Lead optimisation #Regenerative Medicine #Regulatory #RNA #Stem cells #Therapeutics

The Future of Cardiovascular Gene Therapy

The Future of Cardiovascular Gene Therapy By Christopher J. Reinhard Advances in regenerative medicine go hand in hand with new perspectives and insights into potential treatments for heart disease. After a decade of pre-clinical and early Phase 1 and 2 clinical studies, gene therapy is now emerging as a genuine… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Pharmacogenomics #Pharmokinetics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Chemical microarrays – The drug discovery superhighway

Chemical microarrays - The drug discovery superhighway By Elaine Seeskin While producing targets was once the bottleneck in the drug discovery process, in the post-genomic era this has been superseded by the requirement for high-quality lead structures. As a result of the pool of genomic data and countless unvalidated targets… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Pharmacology #Preclinical #Regulatory #RNA #Stem cells #Toxicology

Obesity – The 21st century disease

Obesity - The 21st century disease By Diane L. McBay and Dr Colin T. Dourish Obesity will be the leading cause of death and disability in the 21st century. This epidemic is largely attributable to increasingly sedentary lifestyles and the abundance of tasty, high-fat foods. Obesity increases the risk of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #Preclinical #RNA #Screening #Stem cells #Target validation

Channelling Drug Discovery – Current trends in ion channel drug discovery research

Channelling Drug Discovery - Current trends in ion channel drug discovery research By Dr David Owen and Andrew Silverthorne Ion channels are proteins that span cell membranes thus forming conduits or 'channels' through which charged ions such as sodium and potassium can pass across a normally impermeant barrier such as… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #In Silico Biology #Lead discovery #Oncology #Pharmacogenomics #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companiessq

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies of scale enjoyed… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #Lead discovery #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Business strategy for implementation of biomarkers in drug development

Business strategy for implementation of biomarkers in drug development By Miles Flamenbaum With pharmacoproteomic biomarkers being the subject of focus among regulatory agencies as well as research institutions, many pharmaceutical companies are increasing their interest and investment in biomarker strategies. This article discusses the potential for new efficiencies and cost… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genomics #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Target validation #Toxicology

From raw data in the laboratory to information availability in the enterprise

From raw data in the laboratory to information availability in the enterprise By Dieter Kreusel If pharmaceutical or biotechnology companies could measure their success merely on the volume of raw data accumulated from screening assays and pre-clinical testing, they would be basking in the glow of unprecedented success. Companies are… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology

Toxicogenomics – Insights into the present and future

By Dr Patrick J. Vojta, Vincent P. Kazmer and Dr Larry D. Kier Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on genomic responses or toxicogenomics (1). This article… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Gene therapy #Genomics #High Content Screening #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology

Metabolism Provides Alternative Door to Stroke Therapy

Metabolism Provides Alternative Door to Stroke Therapy By Dr Keith F. Martin and Tony Dolan Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs. You know that feeling you get the day after an exaggerated attempt at physical… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Biochemistry #Cellular & Molecular biology #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High throughput screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Proteomics In Drug Target Discovery – High-throughput meets high-efficiency

Proteomics In Drug Target Discovery - High-throughput meets high-efficiency By Dr Terence E. Ryan and Dr Scott D. Patterson Biochemistry is enjoying a renaissance under the guise of 'proteomics' due to the availability of sequenced genomes, advances in mass spectrometry and associated data analysis. Its application to drug discovery and… Read More

#Archive

#Academic #ADME / Tox #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Organic chemistry #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Cell Based Assays – Seeing the light

Cell Based Assays - Seeing the light By Dr Nick Thomas High-context cell assays have the potential to take the pivotal role in the drug discovery process. So what are the features of today's leading edge cell based assay technologies and where does the future lie? We live in interesting… Read More

#Archive

#AI / data analytics / healthtech / informatics #Assay development & optimisation #Automation / robotics #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Microbiology #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Pharmokinetics #Precision medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Silicon Technology and Pharmaceutics

Silicon Technology and Pharmaceutics by Professor Leigh T. Canham, Dr Roghieh S. Saffie, Stephen E. Connor and Dr Roger Aston The recent discovery that, following nanostructuring, silicon can be rendered biocompatible and biodegradable has far reaching and profound long-term implications for the pharmaceutical industry and, indeed, medicine as a whole. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Target validation #Therapeutics

A Revolution in R&D – The managerial challenges

The genomics revolution is poised to sweep aside the old economics of pharmaceutical R&D. The biotechnology and pharmaceutical industries; and perhaps healthcare delivery in general; are on the brink of transformation, and companies that embrace the revolution in the right way stand to reap enormous benefits. Developing a new drug… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Protein chemistry / Proteomics #RNA #Screening #Stem cells

Hit to lead and lead to candidate optimisation using multi-parametric principles

Hit to lead and lead to candidate optimisation using multi-parametric principles By Dr Anthony D. Baxter and Dr Peter M. Lockey As the numbers of potential target proteins become available for pharmaceutical companies of all sizes, the drive towards more cost-effective drug discovery assumes greater significance. It is a truism… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Clinical trials #Drug development #Drug discovery #Genomics #High Content Screening #High throughput screening #Lead discovery #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation

Data Mining in the pharmaceutical industry

Data Mining in the pharmaceutical industry By Dr Robert D. Small and Herbert A. Edelstein A research-based pharmaceutical company is a data accumulating wonder. More than in any other industry, success is predicated on the collection, processing and exploitation of that data. This is not always recognised and often not… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Cell culture #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #Therapeutics #Toxicology

Evaluating future drug candidates and their manufacture together

Evaluating future drug candidates and their manufacture together By Professor Peter Dunnill Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being… Read More

#Archive